Certara paper shows viral kinetic modeling grows flu knowledge, advances drug development

(Rana Healthcare Solutions LLC) As the number of drug-resistant influenza strains grows, and the challenge to identify the best strains to include in the next year’s vaccine continues, researchers are searching for better ways to develop safer, more effective anti-viral drugs. Viral kinetic modeling, combined with pharmacokinetic/pharmacodynamic modeling, is proving a fruitful resource. Certara’s review paper in Current Pharmacology Reports highlights the benefits of combining mathematical modeling types to maximize the use of all pre-clinical, clinical and epidemiological data.